SECuRE trial (Cu 67) advances: No dose limiting toxicities and strong preliminary efficacy data

[Maxone73]

It keeps being promising, but keep an eye also on Pb 212, which on paper should be even better for prostate cancer.

After 2 cycles: "Early preliminary efficacy assessment shows a reduction in PSA levels following treatment in both participants who have completed the DLT period. In the weeks following the last therapy dose, these participants have already exhibited PSA drops of more than 60%. The largest drop in PSA to date was a fall of 92.3% (from a baseline PSA of 157.4 ng/mL), and it continues to decline based on the latest assessment. This participant, who had failed several lines of therapy prior to receiving 67Cu-SAR-bisPSMA (i.e. androgen deprivation therapy [ADT], androgen receptor pathway inhibitor [ARPI] and an investigational agent through a clinical trial), has already had a radiographic partial response based on Response Evaluation Criteria in Solid Tumours v1.1 (RECIST) assessment, with a reduction of 60.6% in tumour volume evaluated by PSMA positron emission tomography (PET) imaging thus far "

prnewswire.com/news-release...

[KocoPr]

That is awesome news

[Bkraus1]

That’s great to hear. This may replace the diagnostic gallium PSMA scans. Hopefully this works better than lutetium as well. If I recall, they did report a complete response in their phase 1 trials as well. Keep us posted!

[littleCar]

This is great news! Helps offset the bad news about ONCT-534. They two might have been an impressive combo.

[Maxone73 in reply to littleCar]

I was hoping as well!

[lokibear0803]

Can you describe what it is about Pb-212 that should make it better? Pharmacologically, biologically, etc. Thanks Maxone!

[Maxone73 in reply to lokibear0803]

Well, first of all it’s an alpha emitter and not a beta emitter like lutetium. Which means more energy (=more damage to cancer cells) concentrated in a smaller area (= less damage to healthy cells). It has short half-life, which means that the treatment can be repeated more often (lower dosage more frequently should reduce side effects) and interact more synergistically with the immune system. In a nutshell, short half life means that lead won’t hit the car T cells and other immune cells that are generated by the body days after the treatment. With emitters that have a long half-life you risk to hit also the immune system itself. Plus it’s not has hard to manufacture as actinium, which makes I easier to deploy. We will see if these advantages are on paper only! This is what I remember, but if you look in my past posts I think I have posted a link about dr sartor talking about it.

[lokibear0803]

Nice summary - many thanks!

[Soumen79]

What seems most promising is ”some cases, almost 5 months after receiving one single dose of the product"

Hope this will be durable and due to less toxicity can be applied repeated times